Pfanstiehl, Inc.
Hem Sunder Reddy, a seasoned professional in the biotechnology and pharmaceutical sectors, currently serves as the Director-Asia Pacific at Pfanstiehl, Inc., overseeing the development of high-purity sugars and high-potency active pharmaceutical ingredients since October 2018. Previously, Hem held roles at GE Healthcare, including Senior Product Manager and Sales Manager, where responsibilities included sales management and product management for bioprocess technologies. Further experience includes Business Manager positions at Thermo Fisher Scientific and research roles at Life Technologies, Serum Institute of India Limited, Wockhardt, Sanofi (Shantha Biotech), and Dr. Reddy's Laboratories. Hem holds a Master’s Degree in Biochemistry and Molecular Biology from Acharya Nagarjuna University and a Bachelor’s Degree in Biochemistry, Biophysics, and Molecular Biology from Andhra University.
This person is not in any teams
This person is not in any offices
Pfanstiehl, Inc.
1 followers
Founded in 1919 by Carl A. Pfanstiehl, our company specializes in isolation, purification, custom synthesis and scale-up development of cGMP, high purity and low endotoxin (HPLE) Injectable Formulation Components, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API’s), in gram to multi-ton commercial quantities. Tried and true parenteral excipients include trehalose, sucrose, mannitol, maltose, sorbitol, and hydroxypropyl betacyclodextrin. Upstream, high purity media components include animal component free galactose, mannose, and L-arginine. At Pfanstiehl we pride ourselves on being customer focused and are amenable to producing cGMP components on a custom basis to solve formulation challenges for our clients.